Evidence map›Paper›PMID 41635463›Full record

ArticleFrontiers in bioinformatics2025

TRANSAID: a hybrid deep learning framework for translation site prediction with integrated biological feature scoring.

Yan Li, Boran Wang, Zhen Liu, Wei Wei, Caiyi Fei, Shi Xu, Tiyun Han, Wei Geng, Zengding Wu

Abstract read
In one paragraph

Article in Frontiers in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yan LiDepartment of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Boran Wang *Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Zhen Liu *Breast Disease Diagnosis and Treatment Center, Affiliated Hospital of Qinghai University, Affiliated Cancer Hospital of Qinghai University, Xining, China.
Wei Wei *Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Caiyi FeiDepartment of AI and Bioinformatics, Nanjing Chengshi Biopharmaceutical (TheraRNA) Co., Ltd., Nanjing, China.
Shi XuDepartment of AI and Bioinformatics, Nanjing Chengshi Biopharmaceutical (TheraRNA) Co., Ltd., Nanjing, China.
Tiyun HanDepartment of AI and Bioinformatics, Nanjing Chengshi Biopharmaceutical (TheraRNA) Co., Ltd., Nanjing, China.
Wei GengDepartment of AI and Bioinformatics, Nanjing Chengshi Biopharmaceutical (TheraRNA) Co., Ltd., Nanjing, China.
Zengding Wu *Department of AI and Bioinformatics, Nanjing Chengshi Biopharmaceutical (TheraRNA) Co., Ltd., Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Translation initiation and termination are critical regulatory checkpoints in protein synthesis, yet accurate computational prediction of their sites remains challenging due to training data biases and the complexity of full-length transcripts. Methods: To address these limitations, we present TRANSAID (TRANSlation AI for Detection), a novel deep learning framework that accurately and simultaneously predicts translation initiation (TIS) and termination (TTS) sites from complete transcript sequences. TRANSAID's hierarchical architecture efficiently processes long transcripts, capturing both local motifs and long-range dependencies. Crucially, the model was trained on a human transcriptome dataset that was rigorously partitioned at the gene level to prevent data leakage and included both protein-coding (NM) and non-coding (NR) transcripts. Results: This mixed-training strategy enables TRANSAID to achieve high fidelity, correctly identifying 73.61% of NR transcripts as non-coding. Performance is further enhanced by an integrated biological scoring system, improving "perfect ORF prediction" for coding sequences to 94.94% and "correct non-coding prediction" to 82.00%. The human-trained model demonstrates remarkable cross-species applicability, maintaining high accuracy on organisms from mammals to yeast. Beyond annotation, TRANSAID serves as a powerful discovery tool for novel coding events. When applied to long-read sequencing data, it accurately identified previously unannotated protein isoforms validated by mass spectrometry (76.28% validation rate). Furthermore, homology searches of high-scoring ORFs predicted within NR transcripts suggest a strong potential for identifying cryptic translation events. Discussion: As a fully documented open-source tool with a user-friendly web server, TRANSAID provides a powerful and accessible resource for improving transcriptome annotation and proteomic discovery.

Indexed as

cross-species analysisdeep learningintegrated scoring systemopen reading frametranscriptome annotationtranslation site prediction

Identifiers

PMID41635463
PMCPMC12862215

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.